Edwards Lifesciences (NYSE:EW) had its target price boosted by Jefferies Financial Group from $168.00 to $180.00 in a research report report published on Thursday morning, MarketBeat.com reports. Jefferies Financial Group currently has a buy rating on the medical research company’s stock. Jefferies Financial Group also issued estimates for Edwards Lifesciences’ Q1 2019 earnings at $1.35 EPS, Q2 2019 earnings at $1.33 EPS, Q4 2019 earnings at $1.29 EPS, FY2019 earnings at $5.22 EPS, FY2020 earnings at $5.86 EPS, FY2021 earnings at $6.57 EPS and FY2022 earnings at $7.42 EPS.

EW has been the topic of a number of other reports. Guggenheim lowered shares of Edwards Lifesciences from a buy rating to a neutral rating in a research note on Tuesday, October 2nd. Zacks Investment Research raised shares of Edwards Lifesciences from a hold rating to a buy rating and set a $185.00 target price on the stock in a research note on Wednesday, September 26th. ValuEngine raised shares of Edwards Lifesciences from a hold rating to a buy rating in a research note on Wednesday, September 19th. SunTrust Banks raised their target price on shares of Edwards Lifesciences to $200.00 and gave the stock a buy rating in a research note on Friday, September 28th. Finally, Bank of America lowered shares of Edwards Lifesciences from a buy rating to a neutral rating in a research note on Tuesday, October 2nd. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have issued a buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $162.85.

Shares of NYSE:EW traded down $5.84 during trading on Thursday, reaching $157.50. 385,895 shares of the company’s stock traded hands, compared to its average volume of 1,278,365. Edwards Lifesciences has a fifty-two week low of $110.68 and a fifty-two week high of $175.00. The company has a quick ratio of 1.85, a current ratio of 2.31 and a debt-to-equity ratio of 0.18. The stock has a market capitalization of $32.89 billion, a PE ratio of 41.45, a price-to-earnings-growth ratio of 2.07 and a beta of 0.90.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, October 23rd. The medical research company reported $1.07 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.02 by $0.05. Edwards Lifesciences had a net margin of 20.67% and a return on equity of 30.11%. The firm had revenue of $906.60 million for the quarter, compared to analyst estimates of $927.56 million. During the same period last year, the company posted $0.84 EPS. Edwards Lifesciences’s quarterly revenue was up 10.4% compared to the same quarter last year. Sell-side analysts expect that Edwards Lifesciences will post 4.7 earnings per share for the current fiscal year.

In related news, Director William J. Phd Link sold 13,578 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, November 19th. The shares were sold at an average price of $149.92, for a total value of $2,035,613.76. Following the completion of the sale, the director now owns 16,730 shares in the company, valued at approximately $2,508,161.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Catherine M. Szyman sold 700 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, October 15th. The shares were sold at an average price of $142.64, for a total transaction of $99,848.00. Following the completion of the sale, the vice president now owns 27,772 shares of the company’s stock, valued at approximately $3,961,398.08. The disclosure for this sale can be found here. Insiders have sold a total of 183,356 shares of company stock valued at $27,011,207 in the last 90 days. Insiders own 1.84% of the company’s stock.

Several large investors have recently bought and sold shares of EW. Voya Investment Management LLC lifted its position in Edwards Lifesciences by 47.9% in the second quarter. Voya Investment Management LLC now owns 911,238 shares of the medical research company’s stock valued at $132,649,000 after acquiring an additional 295,113 shares during the last quarter. Global X Management Co LLC lifted its position in Edwards Lifesciences by 13.4% in the second quarter. Global X Management Co LLC now owns 11,327 shares of the medical research company’s stock valued at $1,649,000 after acquiring an additional 1,342 shares during the last quarter. OppenheimerFunds Inc. lifted its position in Edwards Lifesciences by 5.7% in the second quarter. OppenheimerFunds Inc. now owns 161,270 shares of the medical research company’s stock valued at $23,476,000 after acquiring an additional 8,684 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its position in Edwards Lifesciences by 3.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 794,667 shares of the medical research company’s stock valued at $115,680,000 after acquiring an additional 26,346 shares during the last quarter. Finally, Highstreet Asset Management Inc. lifted its position in Edwards Lifesciences by 14.3% in the second quarter. Highstreet Asset Management Inc. now owns 5,959 shares of the medical research company’s stock valued at $867,000 after acquiring an additional 744 shares during the last quarter. Institutional investors and hedge funds own 82.55% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Recommended Story: Intrinsic Value and Stock Selection

Analyst Recommendations for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.